top of page

In-vitro diagnostics (IVD)

体外診の帯.png

Top > In-vitro diagnostics (IVD) > COVID-19 Antigen Test Kit

en_抗原検査キット10回用バナー.png

※Ability to detect the Omicron variant has been confirmed and reported to the MHLW.

We have started to provide the novel coronavirus (COVID-19) antigen test kit (for medical use) to companies and organizations.

​

Customers who want to purchase from a company, organization, local government, etc., please note the following in advance in accordance with the Ministry of Health, Labour and Welfare guidelines.​

​

＜Inquiries about this product (purchase, quotation)＞

　E-mail：st_support@cellspect.com
　TEL：019-681-2099

​

＜ References of Ministry of Health, Labour and Welfare guidelines ＞

　→Procedures for Conducting Inspections in the Workplace(3rd Edition) (the Ministry of Health, Labour and Welfare)

PDFファイルアイコン2.png

（pdf ）

Intended use

Detection of SARS-CoV-2 antigen in nasopharyngeal or nasal swabs (to aid in the diagnosis of SARS-CoV-2 infection)

Measuring principle

This assay is based on immunochromatographic technology using monoclonal antibodies against SARS-CoV-2 antigen. The test stick consists of a sample well, a conjugate pad containing colored nanoparticle-labeled anti-SARS-CoV-2 monoclonal antibody (rabbit) (hereinafter, the colored nanoparticle-antibody), a membrane immobilized with anti-SARS-CoV-2 monoclonal antibody (mouse) (hereinafter, a capture antibody) and an anti-rabbit immunoglobulin polyclonal antibody (goat).

Overall View of the Test Stick

En_テストスティック.png

​Sample dropped on the sample well of the test stick will flow into the conjugate pad due to the capillary phenomenon. The colored nanoparticles-labeled antibody in the conjugate pad will dissolve in the specimen and form the antigen-antibody complex with the SARS-CoV-2 antigen in the sample. The formed antigen-antibody complex continuously move to the membrane and is captured with the capture antibody immobilized on the membrane. The colored nanoparticles of the captured antigen-antibody complex will appear as a red line on the [T1] in the test window. In this kit, appearance of this red line can be visually confirmed to determine the presence of SARS-CoV-2 antigen in the specimen. In addition, the non-complexed antibody conjugated with red nanoparticles will move to the [C] in the test window and be captured with polyclonal antibody against rabbit immunoglobulin immobilized on the membrane. The colored nanoparticles of the captured non-complexed antibody will appear as a red line on the [C] in the test window, indicating that the test is performing successfully.

Measuring Principle

測定原理図矢印.png

Flow direction

En.測定原理図.png
En.測定原理図2.png

Performance

1. Performance

When tests of sensitivity, accuracy, and reproducibility are performed with a positive control (0.5 ng/test) and a negative control (buffer) in accordance with the procedure in the "Test Procedure", this kit meets the following standards.

​

A) Sensitivity

"Positive" is confirmed when the positive control is tested as a sample. 

​

B) Accuracy

When the positive control and negative control are tested as samples, "Positive" is confirmed for the positive control and "Negative" is confirmed for the negative control. 

​

C) Reproducibility

When the positive control and negative control are measured three times for each sample, all positive controls are confirmed to be "Positive" and all negative controls are confirmed to be "Negative". 

​

2. Limit of detection

The limit of detection of this kit is 0.1 ng/test.

​

3. Cross-reactivity

 (1) Viruses other than SARS-CoV-2

        Influenza Type A virus protein, Flu A protein (NP Antigen)

        Influenza Type B protein (TOKIO) 

 

 (2) Other coronaviruses

       Coronavirus （HCoV-229E） Nucleoprotein

       Coronavirus （HCoV-OC43） Nucleoprotein

       Coronavirus （HCoV-HKU1） Nucleoprotein

 

No cross-reactivity was detected in all viruses listed in above (1) and (2).

​

4. Information on reference standard for calibration

Cellspect Co. Ltd in-house reference standards.

​

5. Clinical performance data 

　 5.1. Nasopharyngeal swab

　       (1) Correlation between this kit and RT-PCR test (reference: 3)

                a) All samples (cryopreserved samples and on-site samples)

5-1(1)a (英語).png

Positive agreement: 74%

Negative agreement ：98%

Overall agreement ：84%

※ There was one case where this kit was positive and the RT-PCR test was negative. This patient tested positive for RT-PCR the day after sampling.

2) Cryopreserved samples

5-1(1)b (英語) .png

Positive agreement ： 67% 
Negative agreement ：100%  
Overall agreement ： 75% 

c) On-site samples (patients from clinical facilities)

5-1(1)c (英語) .png

Positive agreement ：76%  
Negative agreement ：98% 
Overall agreement ：87% 

(2) Positive agreement between samples tested positive by RT-PCR and this kit

a) All samples (cryopreserved samples and on-site samples)  

5-1(2)a (英語).png

b) Cryopreserved samples

5-1(2)b (英語).png

c) On-site samples (patients from clinical facilities)

5-1(2)c (英語).png

※ The estimated amount of RNA (copies/5 µL) was adjusted with Ct (cycle threshold) value calculated under the hypothesis that extraction ratio of RNA and other standard molecules in the sample were the same.

※ The copy numbers of virus (copy/test) show the viral load in one RT-PCR test.  

※ The positive agreement for samples with more than 1,000 viral copies/test by the RT-PCR test of set N2 was 90% in all samples, 100% in cryopreserved samples  and 88% in on-site clinical samples.

5.2. Nasal swab

(1) Correlation between this kit and RT-PCR test

a) All samples (cryopreserved samples and on-site samples)  

5-2(1)a (英語).png

Positive agreement ： 59% 
Negative agreement：100%  
Overall agreement： 77% 

b) Cryopreserved samples

5-2(1)b (英語) .png

Positive agreement ： 69% 
Negative agreement：100%  
Overall agreement ： 80% 

c) On-site samples (patients from clinical facilities)

5-2(1)c (英語) .png

Positive agreement ： 56%  
Negative agreement：100％  
Overall agreement： 76% 

(2) Positive agreement between samples tested positive by RT-PCR and this kit

a) All samples (cryopreserved samples and on-site samples)  

5-2(2)a (英語) .png

b) Cryopreserved samples

5-2(2)b (英語) .png

c) On-site samples (patients from clinical facilities)  

5-2(2)c (英語) .png

※ The estimated amount of RNA (copies/5 µL) was adjusted with Ct (cycle threshold) value calculated under the hypothesis that extraction ratio of RNA and other standard molecules in the sample were the same.
※ The copy numbers of virus (copy/test) show the viral load in one RT-PCR test.  
※  The positive agreement for samples with more than 1,000 viral copies/test by the RT-PCR test of set N2 was 82% in all samples, 100% in cryopreserved samples  and 78% in on-site clinical samples.

Storage method and expiration date

1. Storage Method: 2 ~ 8 °C

2. Validity Period: 24 months from the date of manufacture

Packaging unit

IQVALF101   Quampas COVID-19 Antigen Test Kit 10 tests

IQVALF011   Quampas COVID-19 Antigen Test Kit 1 test

References

  1. WHO Website : : “Naming the coronavirus disease (COVID‐19) and the virus that causes it (https://www.who.int/emergencies/diseases/novelcoronavirus- 2019/technical-guidance/naming-thecoronavirus- disease-(covid-2019)-and-the-virus-thatcausesit#:~: text=Official%20names%20have%20been%20announ ced,%2DCoV%2D2)

  2. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO Kobe Center published in Japanese

  3. The Coronavirus Disease 2019 (COVID-19) Pathogen Detection Manual, ver2.9.1. National Institute of Infectious Diseases, Japan

  4. Guidelines for the operation of assay for the novel coronavirus (SARS-CoV-2), 3rd edition, National Institute of Infectious Diseases, Japan

  5. Guidelines for testing for novel coronavirus (COVID-19) pathogens, 1st edition, issued on October 2, 2020, MHLW, Japan

Measurement example

An example of use with nasal swab

※ The latest product has been changed from two swabs (one for the nasopharynx and one for the nasal cavity) to one (for both the nasopharynx and nasal cavity).

Swab*1

PDFファイルアイコン2.png

Package insert

Swab*2

PDFファイルアイコン2.png

Package insert

10test

PDFファイルアイコン2.png

Flyer

1test

PDFファイルアイコン2.png

Flyer

Product purchase / inquiry

To purchase this product, please contact the following e-mail address.

 

Email: st_support@cellspect.com

TEL: 019-681-2099

Business hours: Weekdays 9: 00 -17: 00 (excluding Saturdays, Sundays, and holidays)

 

*We cannot offer any support other than the utilization and research of this product.  We cannot provide support for the accidental consequences of research activities (such as detection of antibodies suspected of being infected), please consult your local government or agencies.

bottom of page